**ABSTRACT**

Objective: To evaluate the available literature regarding Upper Airway Resistance Syndrome (UARS) treatment. Methods: Keywords “Upper Airway Resistance Syndrome,” “Sleep-related Breathing Disorder treatment,” “Obstructive Sleep Apnea treatment” and “flow limitation and sleep” were used in main databases. Results: We found 27 articles describing UARS treatment. Nasal continuous positive airway pressure (CPAP) has been the mainstay therapy prescribed but with limited effectiveness. Studies about surgical treatments had methodological limitations. Oral appliances seem to be effective but their efficacy is not yet established. Conclusion: Randomized controlled trials with larger numbers of patients and long-term follow-up are important to establish UARS treatment options.

**1. Introduction**

The Upper Airway Resistance Syndrome (UARS) was first named by Guilleminault in 1993 [1] while investigating cases of excessive daytime sleepiness with no identified cause in adults. However, the respiratory pattern of increased upper airway resistance was previously identified in pre-pubertal children under the label “sleep-related respiratory resistive load” [2].

Since this first description, many authors have attempted to describe the clinical and polysomnographic features of UARS patients based on their experience, to find a definitive way to diagnose and finally treat them. In particular, during the last twenty years, the definition of UARS has varied (Table 1). Currently, UARS is subsumed under the diagnosis of Obstructive Sleep Apnea Syndrome (OSAS) by the American Academy of Sleep Medicine (AASM) (Berry AASM 2012) [3].
Table 1 - UARS definitions.

| Authors          | Clinical criteria                           | Polysomnographic criteria                      |
|------------------|---------------------------------------------|------------------------------------------------|
| Kristo et al., 2005 [47] | Excessive daytime sleepiness (ESS >10)       | Pes ≤ 12 cm H2O                                 |
| Guilleminault et al. [7]   | Excessive daytime sleepiness or fatigue    | Pes and flow limitation by nasal cannula        |
| Loube et al., 2009 [48]    | Excessive daytime sleepiness               | Inductance plethysography Pes ≤ 12 cm H2O      |
| Stoohs et al., 2009 [49]   | Excessive daytime sleepiness or fatigue    | Flow limitation by nasal cannula               |
| Pépin et al., 2012 [6]     | Excessive daytime sleepiness               | Pes, flow limitation by nasal cannula          |

ESS: Epworth Sleepiness Scale, Pes: Esophageal pressure, AHI: Apnea / Hypopnea Index, RERA: Respiratory Event-Related Arousal, RDI: Respiratory Disturbance Index

Its diagnostic criterion is still not defined and some authors believe that UARS is part of a continuum between primary snoring and OSAS whereas others believe that it is a distinct syndrome from OSAS. Some authors support that both UARS and OSAS have the same symptoms and as their pathophysiology do not significantly differ from each other, UARS is not a distinct disease [4,5]. Nevertheless, other authors believe that UARS patients present different features than other Sleep related Breathing Disorder (SRBD) [6,7,8]. The most frequent symptoms are excessive daytime sleepiness, fatigue and sleep fragmentation. However, UARS patients also present significantly more often with sleep-onset and sleep-maintenance insomnia, postural hypotension, headaches, gastroesophageal reflux, irritable bowel syndrome, anxiety and alpha-delta sleep [9,10,11]. The proportion of women with UARS is also significantly higher than for OSAS [12]. Besides having some different clinical presentation, it has been suggested that UARS and OSAS differ from each other in terms of their sleep EEG and autonomic nervous system responses. Some authors believe that UARS patients have an increase in alpha rhythm and an over-activation of the autonomic nervous system [13].

UARS diagnosis is suspected in individuals with complaints of excessive daytime sleepiness or daytime tiredness, no OSAS and a polysomnographic study with respiratory parameters indicative of increased upper airway resistance, such as, flow limitation during sleep. They present arousals associated with increase in respiratory effort leading to sleep fragmentation and excessive daytime sleepiness. The polysomnographic studies of these patients also showed sequences of breaths with flow limitation, which were interrupted by abrupt arousals. Arousals were defined using American Sleep Disorders Center-American Academy of Sleep Medicine (AASM) [14,15] conventional criteria but were also described using the cyclic alternative pattern-CAP-atlas, [16] including the shorter duration arousals associated with abnormal increases of “Phase A2” and “Phase A3” of the CAP scoring system and with RERA [17]. The arousals associated with flow limitations were described as “respiratory event related arousals” (RERA) by AASM [14,15]. The polysomnography (PSG) pattern of “flow limitation,” introduced in 1991 [18] was further investigated and defined particularly in New York [19,20] as a sign of increased upper airway resistance to airflow.

Untreated UARS individuals can present low quality of life and cardiovascular consequences. Sleep and daytime symptoms, such as fatigue, insomnia and depressive mood, in untreated UARS usually increase over time [7]. The syndrome’s characteristic esophageic pressure (Pes) negativity can cause a diastolic leftward shift of the interventricular heart septum and a consequent ventricular “collapse”. [21] The longlasting flow limitation episodes can induce a small increase in end-tidal carbon dioxide (PetCO2) that can stimulate the sympathetic nervous system activity. This could cause hypertension, and cardiovascular and metabolic consequences. [6] Even an increase in inflammatory markers can happen in non-treated UARS individuals. [22]

In order to avoid the consequences mentioned above, a proper treatment should be offered to UARS patients. There are some treatment studies available in the literature, but most of these are case reports and case series. Nasal continuous positive airway pressure (CPAP) is one treatment option that has been evaluated as a therapy for UARS, and the available studies demonstrated that it can improve different aspects of the condition. CPAP treatment was associated with significant improvements in the excessive daytime sleepiness, numbers of transient arousals and abnormal upper airway resistance.1 Other types of treatments evaluated included oral appliances, nasal and palatal surgeries and maxillomandibular advancement. Long-term studies to evaluate treatment response will be helpful to better define this SBD.
The following sections review the available literature describing UARS treatment.

2. Methods

A systematic search of articles covering 1982 to date using Medline (via PubMed), Scielo, Lilacs, The Cochrane Library and Web of Science was conducted to identify published articles regarding UARS treatment. The search terms used were: “Upper Airway Resistance Syndrome”, “Upper Airway Resistance Syndrome AND treatment”, “Sleep-related Breathing Disorder AND treatment”, “Obstructive Sleep Apnea AND treatment” and “flow limitation AND sleep”. “Sleep apnea, obstructive” is a MeSH (Medical Subject Heading) in PubMed, and we used the subheadings “diet therapy,” “drug therapy,” “surgery” and “therapy” to improve the search. Articles describing either adult or pediatric populations were included. Only articles published in English were considered.

The literature search and the screenings of headings and abstracts were made by two different authors (LG and LP) independently. Both of them read all 27 fulltext articles that were assessed for eligibility. If consensus was not achieved, a final decision.

3. Results

We found 457 articles in PubMed and 909 articles in Scielo, Cochrane, Bireme, Lilacs and Web of Science when the keywords “Upper Airway Resistance Syndrome” were used. Only 15 articles focused on UARS treatment, and all the articles included in Scielo, Cochrane, Bireme, Lilacs and Web of Science were also included in PubMed. We considered only once the articles that were identified twice because they were listed in two different sources. We also found 10 UARS systematic reviews that mentioned the syndrome’s treatment along the article. Of the 349 articles found in PubMed using the keyword “Sleep-related Breathing Disorder AND treatment,” none of them were about UARS treatment, and of the 493 articles found in Scielo, Cochrane, Bireme, Lilacs and Web of Science only 1 was about UARS treatment. In PubMed, 5051 articles were found using “Obstructive Sleep Apnea AND treatment” (with its respective MeSH) as the keyword, but only 1 was about UARS treatment. Of the 9147 articles found in Scielo, Cochrane, Bireme, Lilacs and Web of Science when the keyword “Obstructive Sleep Apnea AND treatment” was used, none focused on UARS treatments. Of the 222 articles found in PubMed and from the 678 articles in Scielo, Cochrane, Bireme, Lilacs and Web of Science using the keywords “flow limitation AND sleep,” none described UARS treatments.

Seventeen (17) articles (Table 2) and ten (10) reviews were initially evaluated (Fig. 1). A summary of the original articles evaluated with year and journal of publication, study design, number and characteristics of the patients and conclusions are described in Table 2. The reports consisted mainly of case reports and case series. The main findings are discussed below.

From the 17 articles analyzed, 4 were about CPAP treatment [1,23,24,25], 1 about drug treatment [26], 1 about CPAP and surgery [27], 1 was about rapid palatal expansion [28], 4 about surgery [22–26], 5 about oral device treatment [33–37] and 1 about external nasal device [38]. The definition of UARS also varied. Seven studies considered polysomnographic aspects associated to symptoms such as excessive daytime sleepiness, fatigue or snoring to diagnose UARS. Other studies only considered objective parameters from sleep study. The polysomnographic parameters considered were AHI less than 5–15 events/hour (10 studies) [24,25,27,28,31,32,34,35,37,38], RDI<5–10 events/hour (3 studies) [29,30,33], RDI>5 events/hour (2 studies) [31,35], Pes more negative than 10 or 20 mmH2O (8 studies) [1,23,24,27,29,30,33,35,37,38], the presence of excessive daytime sleepiness or fatigue or snoring (9 studies) [22,25,26,29,32,33,36,38] and presence of RERA or flow limitation (3 studies). [25,27,28]

In summary, therapeutic data about UARS treatment are few and consists of CPAP, oral device, surgery and external nasal device. There are no UARS cohorts with long-term treatment and follow-up available. Most studies about UARS treatment are observational and case reports. There were only two randomized double-blind, placebo-controlled studies published. Indeed, most studies have an inadequate methodology with a small number of patients and without precise sample estimation.

4. Discussion

Mild SBD criteria and events identification have been subject of discussion. The diagnosis of UARS is still controversial. Currently, UARS is considered part of Obstructive Sleep Apnea Syndrome (OSAS) by the AASM. OSAS is defined as the presence of more than 5 obstructive events per hour associated with symptoms or more than 15 events per hour independent of symptoms. Currently, there is no data with outcomes available defining the cut off limit for RERAs and Respiratory Disturbance Index (RDI) in SBD patients, as well as, on healthy individuals. Respiratory index, such as, apnea/hypopnea index (AHI) and RDI has been used with different definitions and considering different respiratory events. There are still several issues that need to be better defined and established regarding UARS, however, most authors today agree that sleep breathing disorders cannot be limited just to OSAS criteria.

CPAP is the UARS treatment modality better investigated. [1,23,24] One month of therapeutic trial with nasal CPAP can significantly change objective polysomnographic parameters [1] and subjective complaints. [1,23,24] CPAP treatment was associated to decrease in transient arousals, increase in percentage of NREM stages 3 and 4 and the sleep latency at MSLT. [1] Subjective daytime sleepiness, fatigue [1,23] and snoring [24] also can improve after CPAP treatment. Nevertheless, in some studies there were patients that did not have their excessive daytime sleepiness and fatigue decreased after CPAP treatment [24]. Consequently, these patients did not comply with CPAP due to the lack of beneficial effects [24]. Even though CPAP may be an effective treatment for UARS, the compliance is low in this patient population. Also, in follow up studies a significant part of patients did not use the
recommended nasal CPAP treatment due to refusal by the insurance companies to cover its prescriptions, on the basis that according to their policies, UARS did not meet the criteria for a CPAP prescription [7].

Auto-CPAP was indicated to treat pregnant women with severe preeclampsia and flow limitation [25]. The mean overnight blood pressure was markedly reduced during the night of treatment with nasal CPAP when compared with the nontreatment night. The authors suggest that nasal CPAP may be considered as a therapy to improve blood pressure control in women with severe preeclampsia and flow limitation.

Medications that decrease sleep fragmentation could be also helpful for UARS patients. 7.5 mg Zopiclone during 1 week produced significant improvements in the sleep efficiency index and average sleep latency in MSLT [26]. Nevertheless, it had no effect on respiratory parameters during sleep and daytime sleepiness in patients with UARS. Despite some improvements demonstrated objectively in the polysomnography, Zopiclone use did not decrease UARS symptoms. It was concluded that medications that consolidate sleep could be an adjuvant medicine used during the main treatment of UARS patients.

Sleep fragmentation persists in many patients with insomnia despite an adequate insomnia treatment. The sleep fragmentation associated with UARS can cause daytime fatigue and enhance anxiety, factors that can increase the difficulty in treating chronic insomnia. Postmenopausal women with chronic insomnia and UARS had their daytime fatigue decreased after nasal treatment (nasal radio-frequency ablation of turbinate or septoplasty with turbinectomy) and nasal CPAP treatment [27]. This study reinforce the idea that SBD should be investigated in patients with chronic insomnia to guarantee an adequate insomnia treatment result.

Psychiatric patients may also present SDB. A case report about a young man with treatment-resistant depression and with sleep symptoms (insomnia, fatigue and daytime sleepiness) was investigated for SDB [28]. As his psychiatric symptoms were not well controlled despite an adequate medical treatment and he had sleep complaints he underwent a sleep...
that UARS treatment consists of approaching the causes of anatomical regions that cause upper airway obstruction and patients. Surgery a long-term effective management for this group of patients. Some authors unwilling to adhere to CPAP therapy. Some authors noticed polysomnographic differences, such as a decrease in the total arousal index (TAI) and lower oxygen saturation. A significant increase in the mean sleep latency in the MSLT and an absence of sleep during the Maintenance of Wakefulness Test (MWT) was also observed. Oral appliance also decreased subjective daytime sleepiness and snoring. Another study report a case of oral appliance indicated for an asthmatic patient with UARS that had poorly controlled asthma symptoms despite high-doses steroids. The post-treatment polysomnography showed normalization of the Pes and decrease in the TAI. Even the asthma symptoms were better controlled and lower doses of drugs were required after the oral device treatment.

The side effects of oral devices observed (excessive salivation and transient tooth discomfort) were minor and tolerable, and no major complications were reported. Objective and subjective aspects of the treatment response were evaluated during a longer follow up. The results demonstrated that oral appliance was effective in decreasing sleep fragmentation and objective and subjective daytime sleepiness and was also well tolerated.

Other types of oral devices besides the mandibular advancement device were also published as case reports but the study did not report clinical or polysomnographic changes pre- and post-treatment. Nasal obstruction is another cause of flow limitation and can lead to occlusion of the pharyngeal airway. The decrease in nasal resistance might also reduce the inspiratory effort. A double-blind, randomized, controlled trial with a cross-over design study was performed to evaluate the effect of external nasal dilatation in UARS patients. The external nasal dilator significantly increased nasal cross-sectional area, reduced stage 1 sleep and decreased desaturation time when comparing to the placebo treatment. These were the only changes observed after treatment. There were no significant effects on the MSLT, AHI or TAI or on the clinical complaints.

Fig. 1 – Flow diagram for identification of articles that were evaluated, excluded and included in the review.

study that showed UARS. The patient was submitted to rapid palatal expansion and during the two-year follow-up remained free from symptoms of depression, anxiety, sleepiness or fatigue in the absence of any psychotropic medication, although there were no statistically significant changes in the polysomnographic parameters. This article reinforces the idea that a sleep study should be included and SBD should be investigated in psychiatric patients who have persistent sleep complaints and whose psychiatric symptoms are not controlled despite an adequate medical treatment.

Upper airway surgeries have also been evaluated as UARS treatment option. Craniofacial abnormalities that may increase upper airway resistance are often present in UARS. Dental malocclusion and elevated ogival hard palate as well as a narrow posterior airway space can be frequent findings in upper airway examination. Surgical treatment were studied UARS patients that preferred surgery (such as septo-midline advancement device were also published as case reports but the study did not report clinical or polysomnographic changes pre- and post-treatment. The only outcome evaluated in these studies were subjective sleepiness and snoring and the follow-up was not long enough to consider surgery a long-term effective management for this group of patients.

Many authors agreed that procedures should address anatomical regions that cause upper airway obstruction and that UARS treatment consists of approaching the causes of the upper airway anatomical problems such as treatment of nasal allergies, usage of palatal soft-tissue surgeries, orthognathic surgery or use of dental devices. Some authors had even tried to formulate a statistical model for postoperative AHI after multilevel surgery in UARS patients. It was concluded that tonsillectomy had a highly significant influence on postoperative AHI.

Concluding, few studies evaluating surgical treatment for UARS are available. Most studies about surgery treatment only consider subjective outcomes and the number of patients has been too low to lead to conclusive results. Many methodological problems in published literature did not allow a proper analysis. Randomized prospective protocols of surgical procedures should be conducted.

Another treatment option for SDB is the use of oral devices. Oral devices move the mandible and tongue forward in order to minimize the oropharyngeal obstruction. Patients with UARS present a narrow posterior airway space behind the base of the tongue. Oral devices increase upper airway dimensions and are often indicated for mild SBD. There are some case reports and a prospective study published about oral device as UARS treatment. Some authors noticed polysomnographic differences, such as a decrease in the total arousal index (TAI), a less negative mean Pes, an improvement in sleep efficiency and lower oxygen saturation. A significant increase in the mean sleep latency in the MSLT and an absence of sleep during the Maintenance of Wakefulness Test (MWT) was also observed. Oral appliance also decreased subjective daytime sleepiness and snoring. Another study report a case of oral appliance indicated for an asthmatic patient with UARS that had poorly controlled asthma symptoms despite high-doses steroids. The post-treatment polysomnography showed normalization of the Pes and decrease in the TAI. Even the asthma symptoms were better controlled and lower doses of drugs were required after the oral device treatment.

The side effects of oral devices observed (excessive salivation and transient tooth discomfort) were minor and tolerable, and no major complications were reported. Objective and subjective aspects of the treatment response were evaluated during a longer follow up. The results demonstrated that oral appliance was effective in decreasing sleep fragmentation and objective and subjective daytime sleepiness and was also well tolerated.

Other types of oral devices besides the mandibular advancement device were also published as case reports but the study did not report clinical or polysomnographic changes pre- and post-treatment. Nasal obstruction is another cause of flow limitation and can lead to occlusion of the pharyngeal airway. The decrease in nasal resistance might also reduce the inspiratory effort. A double-blind, randomized, controlled trial with a cross-over design study was performed to evaluate the effect of external nasal dilatation in UARS patients. The external nasal dilator significantly increased nasal cross-sectional area, reduced stage 1 sleep and decreased desaturation time when comparing to the placebo treatment. These were the only changes observed after treatment. There were no significant effects on the MSLT, AHI or TAI or on the clinical complaints.
The absence of significant clinical changes after treatment, despite the polysomnographic differences, demonstrated that this device, currently, cannot be recommended for the treatment of UARS. Future studies with a larger number of patients and with a longer follow-up should be conducted to better analyze this device’s effects on UARS patients.

5. Conclusion

Currently, there are few well designed studies available of UARS treatment, CPAP has been the primary therapy prescribed, but its effectiveness has been limited because of low patient compliance and there are no randomized controlled trials evaluating this type of treatment in UARS patients. The available studies that have evaluated surgical treatments of UARS patients have methodological limitations and low numbers of patients evaluated. Oral appliances seem to be an effective option, but only case reports and small case series have been reported, and the efficacy of these devices is not yet established for this group of patients. Randomized controlled trials comparing different modalities of treatment with larger numbers of patients and including long-term follow-up are important to better define and establish treatment options in UARS patients.

Conflict of interest

The authors had no conflict of interest in this article.

Acknowledgments

The authors would like to thank for the support by grants from Associação Fundo de Incentivo a Pesquisa (AFIP), Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP), and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

REFERENCES

[1] Guilleminault C, Strohs R, Clerk A, Cetel M, Maistros P, et al. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest 1993;104:781–7.
[2] Guilleminault C, Winkle R, Korobkin R, Simmons B. Children and nocturnal snoring: evaluation of the effects of sleep related respiratory resistive load and daytime functioning. Eur J Pediatr 1982;139:165–71.
[3] Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Levy P. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. Darien, IL: American Academy of Sleep Medicine; 2014 Version 2.1.
[4] Gould GA, Whyte KF, Rhind GB, Airlie MA, Catterall JR, Shapiro CM, et al. The sleep hypopnea syndrome. Am Rev Respir Dis 1988;137:895–8.
[5] Rees K, Kingshott RN, Wraith PK, Douglas NJ. Frequency and significance of increased upper airway resistance during sleep. Am J Respir Crit Care Med 2000;162:1210–4.
[6] Pépin JL, Guilhot M, Tamiérier R, Lévy P. The upper airway resistance syndrome. Respiration 2012;83:559–66.
[7] Guilleminault C, Kirisocglu C, Poyares D, Palombini L, Leger D, Farid-Moayer M, et al. Upper airway resistance syndrome: a long term outcome study. J Psychiatr. Res. 2006;40:273–9.
[8] Gold AR, Gold MS, Harris KW, Espeleta VI, Amin MM, Broderick JE, et al. Hypersomnolence, insomnia and the pathophysiology of upper airway resistance syndrome. Sleep Med 2008;9:675–83.
[9] Gold AR, Dipalo F, Gold MS, O’Hearn D. The symptoms and signs of upper airway resistance syndrome: a link to the functional somatic syndromes. Chest 2003;123:87–95.
[10] Guilleminault C, Strohs R, Kim YD, Chervin R, Black J, Clerk A. Upper airway sleep-disordered breathing in women. Ann Intern Med. 1995;122:493–501.
[11] Guilleminault C, Black JE, Palombini L, Ohayon M. A clinical investigation of obstructive sleep apnea syndrome (OSAS) and upper airway resistance syndrome (UARS) patients. Sleep Med 2000;1:51–6.
[12] Strohs RA, Knaack L, Blum HC, Janicki J, Hohenhorst W. Differences in clinical features of upper airway resistance syndrome, primary snoring, and obstructive sleep apnea/hypopnea syndrome. Sleep Med 2008;9:121–8.
[13] Guilleminault C, Kim YD, Horita M, Tsutumi M, Pelayo R. Power spectral EEG findings in patients with obstructive sleep apnea and upper airway resistance syndromes. Electroencephalogr Clin Neurol 1999;50(Suppl):S109–12.
[14] EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association, 1992. Sleep. 15, 173–84.
[15] Iber C, Ancoli-Israel S, Cheshon Jr. RL, Quan SF. The American academy of sleep medicine manual for the scoring of sleep and associated events: rules, terminology and technical specifications, 1st ed.. Westchester, IL: American Academy of Sleep Medicine; 2007.
[16] Terzano MG, Parrino L, Sherieri A, Chervin R, Chokroverty S, Guilleminault C, et al. Atlas, rules and recording techniques for the scoring of the cyclical alternating pattern-CAP- in human sleep. Sleep Med 2001;2:537–53.
[17] Guilleminault C, Poyares D. Arousal and Upper Airway Resistance. Sleep Med 2002;3:515–20.
[18] Strohs R, Guilleminault C. Snoring during NREM sleep: respiratory timing, esophageal pressure and EEG arousal. Resp Physiol 1991;85:151–67.
[19] Condors R, Norman RG, Krishnasamy I, Peduzzi N, Goldring RM, Rapoport DM. Flow limitation as a noninvasive assessment of residual upper-airway resistance during continuous positive airway pressure therapy of obstructive sleep apnea. Am J Respir Crit Care Med 1994;150:475–80.
[20] Hosselet JJ, Norman RG, Ayappa I, Rapoport DM. Detection of flow limitation with a nasal cannula/pressure transducer system. Am J Respir Crit Care Med 1998;157:1461–7.
[21] Shiomig T, Guilleminault C, Strohs R, Schnittger I. Obstructed breathing in children during sleep monitored by echocardiography. Acta Paediatr 1993;82:863–71.
[22] Vassilakopoulos T, Roussos C, Zakynthinos S. The immune status and upper airway resistance syndrome–report of three cases. Ann Acad Med Singapore 2000;29:242–5.
[23] Ong KC, Cheng PP, Ong YY. Upper airway resistance syndrome–report of three cases. Ann Acad Med Singapore 2000;29:242–5.
[24] Watanabe T, Mikami A, Taniguchi M, Motonishi M, Honda H, Kyotani K, et al. Clinical characteristics of upper airway resistance syndrome. Psychiatry Clin Neurosci 1999;53:331–3.
[25] Edwards N, Blyton DM, Kirjavainen T, Kebby GJ, Sullivan CE, et al. Nasal continuous positive airway pressure reduces sleep-induced blood pressure increments in preeclampsia. Am J Respir Crit Care Med 2000;162:252–7.
[26] Lofaso F, Goldenberg F, Thebault C, Janus C, Harf A. Effect of zopiclone on sleep, night-time ventilation, and daytime sleep science 8 (2015) 42–48
vigilance in upper airway resistance syndrome. Eur Respir J 1997;10:2573–7.

[27] Guilleminault C, Palombini L, Poyares D, Chowdhuri S. Chronic insomnia, premenopausal women and sleep disordered breathing Part 2. Comparison of nondrug treatment trials in normal breathing and UARS post menopausal women complaining of chronic insomnia. J Psychosomatic Res 2002;53:617–23.

[28] Miller P, Iyer M, Gold AR. Treatment resistant adolescent depression with upper airway resistance syndrome treated with rapid palatal expansion: a case report. J Med Case Rep 2012;6:415.

[29] Newman JP, Clerk AA, Moore M, Utley DS, Terris DJ. Recognition and surgical management of the upper airway resistance syndrome. Laryngoscope 1996;106:1089–93.

[30] Utley DS, Shin EJ, Clerk AA, Terris DJ. A cost-effective and rational surgical approach to patients with snoring, upper airway resistance syndrome, or obstructive sleep apnea syndrome. Laryngoscope 1997;107:726–34.

[31] Lewis MR, Ducic Y. Genioglossus muscle advancement with the genioglossus bone advancement technique for base of tongue obstruction. J Otolaryngol 2003;32:168–73.

[32] Tschopp K, Zumbrunn T, Knaus C, Thomaser E, Fabbro T. Statistical model for postoperative apnea-hypopnea index after multilevel surgery for sleep-disordered breathing. Eur Arch Otorhinolaryngol 2011;268:1679–85.

[33] Venkat R, Gopichander N, Vasantakumar M. Four novel prosthodontic methods for managing upper airway resistance syndrome: an investigative analysis revealing the efficacy of the new nasopharyngeal aperture guard appliance. Indian J Dent Res 2010;21:44–8.

[34] Yoshida K. Oral device therapy for the upper airway resistance syndrome patient. J Prostheth Dent 2002;87:427–30.

[35] Bahammam AS, Tate R, Manfreda J, Kryger MH. Upper airway resistance syndrome: effect of nasal dilation, sleep stage, and sleep position. Sleep 1999;22:592–8.

[36] Montserrat JM, Badia JR. Upper airway resistance syndrome. Sleep Med Rev 1999;3:5–21.

[37] Bao G, Guilleminault C. Upper Airway Resistance Syndrome—one decade later. Curr Opin Pulm Med 2004;10:461–7.

[38] Guilleminault C, Los Reyes XD. Upper-airway resistance syndrome. Handb Clin Neurol 2011;98:401–9.

[39] Verse T. Reconstructive procedures for disturbed functions within the upper airway: pharyngeal breathing/snoring. Curr Opin Pulm Med 2004;10:461–7.